Antidepressants in panic disorder: clinical and preclinical mechanisms.
Advances have been made in understanding the biology of panic disorder and the role of the underlying serotonergic dysfunction. This review summarizes the biological evidence for the involvement of serotonin in the pathogenesis of panic disorder and considers the 2 opposing theories that are currently prevalent (5-HT excess and 5-HT deficit). The serotonin selective reuptake inhibitors are increasingly considered as first-line treatment for panic disorder, and the interaction of these agents with the serotonergic system is considered.
The Psychopharmacology Unit, University of Bristol, UK.
D J
DJ
Nutt
D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002997:Clomipramine / Q000627:therapeutic use; D005473:Fluoxetine / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D016584:Panic Disorder / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011903:Raphe Nuclei / Q000737:chemistry / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology; D012701:Serotonin / Q000032:analysis / Q000502:physiology; D018490:Serotonin Agents / Q000494:pharmacology / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000928:Antidepressive Agents; D002997:Clomipramine; D005473:Fluoxetine; D011985:Receptors, Serotonin; D012701:Serotonin; D018490:Serotonin Agents; D017367:Selective Serotonin Reuptake Inhibitors